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Abstract. Therapeutic or diagnostic radiopharmaceutical capsule containing Na131I stays in 
stomach for 15 minutes before the absorption starts, long enough to make possible risky 
exposure. During the oral application it is reasonable to measure effective dose in stomach. 
Direct measurements of organ doses are not possible so there is a strong recommendation to 
estimate them by calculation. The main goal is the 131I risk assessment.  Monte Carlo code 
MCNP4b was used to model the transport of gamma and beta particles emitted by radionuclide 
131I considered as a point source at the bottom of the stomach. Absorbed energy per unit 
transformation in stomach and surrounding organs has been calculated. The dose equivalents in 
these organs have been calculated in aim to determine the effective doses using appropriate 
tissue weighting factor values. Obtained results had not significant importance for radiation 
protection but they were important for establishment of new calibration procedures as a part of 
QA and QC programs in radiopharmaceuticals production and control. 
1.  Introduction 
Capsules containing Na131I are indicated for the therapy of some thyroid carcinomas, for the treatment 
of recurrent hyperthyroidism after surgery but also in nuclear medicine diagnostic techniques.  
The recommended activities for the therapy delivered to the average patient (70 kg) are between 
3.7 GBq and 7.4 GBq for ablation of normal thyroid tissue and for subsequent treatments, between 
148 MBq and 370 MBq for hyperthyroidism  and up to 100 MBq in diagnostics. [1]  For the purpose 
of this paper the nominal dose of  74 MBq  has been chosen   
The administration of Na131I capsules or solutions is oral. In the case of solution absorption in 
gastrointestinal tract starts immediately but in the case of capsules the dissolving time of capsule 
material is 15 minutes. This time is obtained experimentally at VINCA Institute of Nuclear Sciences, 
the manufacturer of the capsules and radiopharmaceuticals based upon 131I. In this time interval some 
amount of radioactivity needlessly expose a part of stomach wall and several surrounding organs. 
These doses are not measurable but could be easily estimated using numerical experiment. Monte 
Carlo technique, also gives a  good and reliable tool for risk assessment. The aim of this paper is to 
show one of the possible way how the additional risk can be estimated.  
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2.  Materials and Methods 
General method for determination of effective dose in different organs and for estimation of additional 
risks is presented as three steps procedure: (1) Dose equivalents in tissues or organs are calculated by 
appropriate radiation transport codes using a suitable mathematical anthropomorphic phantom; (2) The 
effective doses, E, on the basis of tissue weighting factors, has been calculated and (3)  Additional risks 
of lifetime mortality were assessed.  
2.1.  Phantom  
The calculations were performed using a few various anthropomorphic phantoms. [2,3,4,5]. In this 
paper we considered the phantom consists of three major sections: (a) an elliptical cylinder 
representing the trunk and arms; (b) two truncated circular cones representing the legs and feet; and  
(c) a circular cylinder on which sits an elliptical cylinder capped by half an ellipsoid representing the 
neck and head.  
The other organs are modelled by appropriate geometrical figures. The stomach wall is represented 
by the volume between two concentric ellipsoids and the contents by the volume within the inner 
ellipsoid. The wall is defined by equation 1.  
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In the case of adult male the parameters in former equation have the next values: a=4.00, b=3.00, 
c=8.00, d=0.613, x0=8.00, y0=-4.00, z0=35.00  [5] 
As input parameters the three phantom tissue types were recognized: skeletal, lung, and all other 
tissue (soft tissue). The densities of these tissues were: 1.4 gcm-3; 1.04 gcm-3 and 0.296 gcm-3 
respectively. The exact composition of each tissue type is given in ICRP 70, ICRP 89 and ICRU 46  
[6,7,8] The soft tissue composition used in this paper is presented as 10.6 % H + 11.5 % C + 2.2 % N 
+ 75.1 % O + 0.1 % Na + 0.1 % P + 0.1 % S + 0.2 % Cl + 0.1 % K 
 
2.2. Application of MCNP software package 
We used the radiation transport code  MCNP4b, a general Monte Carlo code developed at the Los 
Alamos National Laboratory [9]. In the case of 131I  it is necessary to take gamma rays transport into 
consideration beside beta particles.  Proper tally specification is very important in MCNP simulation. 
For the calculation of gamma dose distribution in different organs *F8 and F6 tallies are applicable 
and therefore used. For beta rays only  we used *F8 tally. These tallies give the absorbed energy in 
organs in units MeV/g per disintegration. For the estimation of local dose distribution in stomach wall 
we used F6 and  *F8 tallies as well as F2 tally applicable only for gammas. [10, 11]. The total number 
of histories was 106. The estimated relative uncertainty of simulation was not higher than 5 %. Due to 
the sphere symmetry estimated uncertainties for calculation of local stomach doses are less than 0.01 
%, and they are negligible. Considering the number of histories obtained uncertainties of Monte Carlo 
calculations of energy imparted in organs are acceptable. 
In the case of 131I  beta particles as well as gamma rays transport should be taken into account. As 
input data for both particles we used beta particles spectra of radionuclide iodine-131 shown in figure 
1 which is converted in the form of histogram (ICRP 1983 and Chul 1999). Our calculated data are 
given in figure 2. As 131I  emits a lot of  gamma photons with discrete energies we used only several 
energies of significant importance, presented in table 1.   
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Figure 1. Beta spectra of 131I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Beta spectra of 131I (histogram version) 
 
 
 
Table 1.  131I photon emission. 
 
Energy (MeV) Fraction 
0.0295 0.0474 
0.0802 0.0262 
0.2843 0.0605 
0.3645 0.8116 
0.6370 0.0748 
0.7229 0.7229 
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3.  Results 
 
In the very first step of calculation MCNP4b software gave us the absorbed energy in the most 
exposed organs as a consequence of 74 MBq 131I  capsule staying in stomach for 15 minutes.  Using 
calculated imparted energies per transformation as well as radiation quality factors we have calculated 
dose equivalent rates in different organs as input parameters for effective dose estimation. Calculated 
values of dose equivalent rate for different organs are presented in table 2. By means of tissue 
weighting factors  and dose equivalent in different organs the effective dose has been calculated and 
presented in table 3. 
 
Table 2.  Calculated values of dose equivalent rate in different organs. 
 
Organ [nSv/s] [µSv/15 min] 
Bladder  222 199 
Bone sur face                                                       12.34 11.12 
Colon                  174.2             156.8 
Liver      2.56 2.30 
Lungs 0.56 0.504 
Ovary, gonads 53.4 48.0 
Skin 2.94 2.66 
 
Table 3.  Calculated values of effective dose in different organs. 
 
Organ Tissue  weighting factor  
 
E   [µSv] 
Bladder                                                       0.05 9.96 
Bone sur face  0.01 11.12x10-5 
Colon 0.12 18.82 
Liver  0.05 11.5x10-2 
Lungs    0.12              6.06 x10-2 
Ovary, gonads 0.20 9.62 
Skin 0.01              2.66 x10-2 
Stomach  0.12 1486 
 
Effective dose at the whole body level is 1.524 mSv. As expected,  this value is relatively small. 
The risk coefficients and calculated risks are presented in table 4.  
The additional risk of cancer death with the value of  13.834 x10-5 is negligible. The same 
situation comes from the calculation of Summary of the Lifetime Mortality in the Whole Population 
from Specific Fatal Cancers after Exposure at Low Radiation Dose and Dose Rates[12].  
These results do not point out to higher risk to the patient but they emphasize the necessity of new 
metrological approach to QA an QC programs in radiopharmaceuticals manufacturing and control.  
As MIRD is used for the calculation of average organ doses and is not capable to recognize the 
local doses we applied Monte Carlo code. These calculations have been performed by MCNP4b 
package for the point source iodine-131 in the soft tissue. For beta dose *F8 tally and for gamma dose 
both *F8 and F2 tallies have been used. Due to the sphere symmetry, estimated uncertainties are less 
than 0.01 %, and they are not significant. The dose-distance profile is presented in figure 3. 
In the vicinity of the capsules we obtained high dose values in order of two grays. Space dose 
fractionation has to be taken into account. These results indicate that the concept of average organ or 
tissue dose must be recruited by additional calculations. 
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Table 4.  The risk coefficients and calculated risks for different organs. 
 
Organ Risk coefficient (10 -2Sv-1) 
 
Risk (x10-5)                                                                  
Bladder                                                      0.30 5.98x10-2 
Bone surface  0.05 5.56x10-7 
Colon 0.80 4.54x10-2 
Liver 0.15                 3.46x10-4 
Lungs    0.85                 4.03x10-4 
Ovary, gonads 0.10                 4.80x10-3 
Skin 0.02                 5.30x10-5 
Stomach  1.10 13.62 
Total r isk   13.834 
 
The following example could serves as a good illustration of organ fractionation dose. Point source 
of 131I  is in the middle of the soft tissue sphere. The average dose in the sphere of radius r  has been 
calculated by MCNP4b code. The average doses in a function of sphere mass for the point source 
activity of 3.7 GBq are presented in figure 4. It was reasonable to presume the point source geometry 
as the small dried drop deposited on the capsule holder. Self-absorption in such source should not be 
significant. 
 
Figure 3. Dose-distance profile 
 
4.  Conclusion 
The investigations and calculations were started with assumption that the values of additional effective 
doses or risks during the 15 minutes of  131I  capsules retaining in the stomach before their absorption 
are not negligible.  Application of solution has some advantages as the absorption in stomach wall is 
immediate but also has a lot of disadvantages. Capsules containing Na131I are widely used as they are 
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more comfortable for administration and there is less possibility for local contamination of patient and 
medical staff.  
The recommended activities for the diagnostic purposes for an average patient (70 kg)  are in the 
range from 50  MBq to 100 MBq  depending of  the thyroid mass. As the administration of Na131I 
capsules is oral they retain in stomach for at least 15 minutes before absorption starts. During that time 
a large amount of radioactivity needlessly expose a part of stomach and several surrounding organs. 
This fact was the main reason for our prediction about the necessity of additional risk estimation. 
Obtained results indicate that values of local doses in stomach wall could not be ignored. As it is not 
possible to measure these doses directly Monte Carlo calculation seems to be good solution for this 
problem. According to the obtained results we recommended some corrections of the traditional 
concept of risk estimation in our hospitals and we emphasized the necessity  to create the concept 
which is able to cover higher risks under presented circumstances. We strongly recommend the 
estimation of additional risks for each type of the procedure as a part of QA programs for  Na131I 
capsules application.  
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